Description This expert review was commissioned and approved by the AGA Institute
Clinical Practice Updates Committee and the AGA Governing Board to provide timely …

Portal vein thrombosis unrelated to solid malignancy is common in patients with cirrhosis,
but less frequently observed in patients without cirrhosis. Prompt diagnosis and …

The prevention and management of bleeding and thrombosis in patients with cirrhosis
poses several difficult clinical questions. These Clinical Practice Guidelines have been …

Vascular disorders of the liver, although affecting less than 5/10,000 patients, collectively
account for a number of rare conditions that represent an important health problem …

Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries
have important clinical consequences and may lead to acute liver failure, chronic liver …

Patients with liver diseases acquire complex alterations in their hemostatic system that may
lead to abnormalities in routine diagnostic test of hemostasis. Thrombocytopenia …

Abstract Background and Aims Direct oral anticoagulants (DOAC) are important new
anticoagulant therapies that are not well studied in patients with chronic liver disease. The …

Patients with acute and chronic liver disease frequently acquire unique changes in
haemodynamic and haemostatic pathways that may result in life-threatening bleeding and …

Background & Aims Non-alcoholic fatty liver disease (NAFLD) is characterized by increased
risk of cardiovascular events and liver-fibrosis. Both could be explained by a procoagulant …

Liver disease results in complex alterations of all 3 phases of hemostasis. It is now
recognized that hemostasis is rebalanced in chronic liver disease. The fall in clotting factor …